Clinical Edge Journal Scan

Forearm BMD and fracture incidence in postmenopausal women with osteoporosis


 

Key clinical point: Abaloparatide/alendronate treatment shows numerically lower risks for wrist fractures compared with placebo/alendronate, suggesting a potential correlation between ultradistal (UD) radius bone mineral density (BMD) and wrist fracture.

Major finding: BMD gains at the UD radius following treatment with abaloparatide in ACTIVE were maintained over the subsequent 24 months of treatment with alendronate in ACTIVExtend (cumulative month 43 treatment difference, 0.89%; P = .20). Conversely, UD radius BMD in the placebo group during ACTIVE decreased to below ACTIVE baseline.

Study details: The data come from a subanalysis of the phase 3 ACTIVExtend trial.

Disclosures: Funding for this study was provided by Radius Health, Inc. NB Watts, RK Dore, and MS LeBoff reported ties with various pharmaceutical companies. B Mitlak and Y Wang were employees of and own company stock in Radius Health, Inc. G Hattersley was a former employee of and a consultant to Radius Health, Inc. TD Rozental is the Editor in Chief of the Journal of Hand Surgery Global Online . S Baim reported no conflicts of interest.

Citation: Watts NB et al. Osteoporos Int. 2020 Sep 15. doi: 10.1007/s00198-020-05555-1 .

Next Article: